SLC5A2 and atrial fibrillation: Although the occurrence of AF/atrial flutter (AFL) events in the group receiving SGLT2 inhibitors was lower compared to the placebo group, dapagliflozin did not show a significant reduction in the risk of new-onset AF compared to placebo [32].